Stereotactic Body Radiotherapy vs. Metastasectomy for Soft Tissue and Bone Sarcoma Lung Metastases – A Systematic Review analyzing Safety and Efficacy
Evidence indicates SBRT and surgery provide comparable outcomes for sarcoma- PM, with SBRT offering a more favorable toxicity profile. Though heterogeneous indications and incomplete reporting limit comparability, SBRT should not be viewed solely as fallback for surgically ineligible patients. Treatment should be individualized within a multidisciplinary expert team, integrating patient- and modality-specific factors. Well-designed prospective trials are needed to define relative safety and efficacy.
Authors
- Maria Anna Smolle (ORCID: https://orcid.org/0000-0003-1021-0899)
- Matthias Gückenberger (ORCID: https://orcid.org/0000-0002-7146-9071)
- Philip Heesen
- Sebastian M. Christ (ORCID: https://orcid.org/0000-0001-5330-3820)
- Siyer Roohani (ORCID: https://orcid.org/0000-0002-8232-4994)
- Lena Kretzschmar
- Sylvie Bonvalot (ORCID: https://orcid.org/0000-0001-9726-9732)
- Astrid Heusel
- Aisha Miah (ORCID: https://orcid.org/0000-0001-6946-0820)
- Falk Röder (ORCID: https://orcid.org/0009-0004-7549-0785)
- Maksym Fritsak
Institutions
- Universität Hamburg (DE)
- German Cancer Research Center (DE)
- Medical University of Graz (AT)
- University of Zurich (CH)
- Heidelberg University (DE)
- Paracelsus Medical University (AT)
- University Hospital of Zurich (CH)
- University Medical Center Hamburg-Eppendorf (DE)
- Royal Marsden Hospital (GB)
- Institut Curie (FR)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1016/j.ctro.2025.101097
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00